Charles W. Francis, M.D.

Charles W. Francis, M.D.

Contact Information

University of Rochester Medical Center
School of Medicine and Dentistry
601 Elmwood Ave, Box 610
Rochester, NY 14642

Professional Bio

Dr. Francis is Professor of Medicine and of Pathology and Laboratory Medicine at the University of Rochester. He obtained his MD degree at the University of Pittsburgh and was then an Intern and Resident in Medicine at the University of North Carolina. He joined the University of Rochester as a Fellow in Hematology in 1976, and he has remained at that institution where he is Director of the Hemostasis and Thrombosis program. Dr. Francis has been recipient of a Clinical Investigator Award from the NHLBI and an Established Investigator Award from the American Heart Association. He has served on numerous NIH Review and Advisory Committees.

He is a past Chairman of the Scientific and Standardization Committee of the ISTH and Program Chair of the XVIIth International Congress on Hemostasis and Thrombosis. He serves as the Editor-in-Chief of Thrombosis Research. Dr. Francis has both clinical and laboratory research interests. Laboratory research has focused on the structure of fibrinogen and fibrin and mechanisms of fibrinolysis. Current work relates to the work of fibrinogen and fibrin in modulating the effects of FGF-2 on endothelial cells. Clinical research has been in the areas of venous thrombosis and new anticoagulants.

Research Bio

Dr. Francis does both clinical and basic research in the areas of thrombosis, hemostasis and vascular biology. Fibrinogen and fibrin have been an area of extensive research. He first described the structures of plasmic degradation products of crosslinked fibrin and developed a molecular model of fibrinolysis. He identified an important structural variant of fibrinogen that differs at the carboxyl terminus of the gamma chain. He was one of the first to demonstrate that ultrasound accelerates enzymatic fibrinolysis, identified the mechanisms responsible and defined the ultrasound parameters for effective fibrinolysis augmentation. Studies in recent years have characterized the interaction of FGF-2, EGF and IL-²

beta with fibrinogen and fibrin. The binding sites for interaction have been identified, and augmented functional activity of FGF-2 and IL-² beta in the bound form demonstrated. Extensive clinical research helped to define the structures of crosslinked fibrin degradation products in fibrinolytic states. Numerous studies have been conducted to improve prophylaxsis of deep vein thrombosis and pulmonary embolism. These have included clinical trials using warfarin, antithrombin, low-molecular-weight heparin and direct thrombin inhibitors. Recent clinical studies have examined risk factors for arterial thrombosis and the effects of thiazolidinediones on lipid and hemostatic risk factors for thrombosis.

Awards & Honors (Local)

Phi Beta Kappa
Alpha Omega Alpha
Established Investigator, American Heart Association
Clinical Investigator Award, National Institutes of Health
Inclusion in "The Best Doctors in America", Woodward/White, Inc, Publishers, 1994, 1995, 1996, 1998, 2000-2006

Recent Journal Articles

Showing the 5 most recent journal articles. 199 available »

A. Moss, C. Francis. "Improving Clinical Practice Guidelines for Practicing Cardiologists". American Journal of Cardiology. 2015; .
B. J. Zaffuto, G. W. Conley, G. C. Connolly, K. F. Henrichs, C. W. Francis, J. M. Heal, N. Blumberg, M. A. Refaai. ""ABO-immune complex formation and impact on platelet function, red cell structural integrity and haemostasis: an in vitro model of ABO non-identical transfusion."". VoxSanguinis The International Journal of Transfusion Medicine 2015 September 11; 1-4. 2015; : 1-4.
Spinelli, Sherry L; Lannan, Katie L; Casey, Ann E;Croasdell, Amanda; Curran, Timothy M; Henrichs, Kelly F; Pollock, Stephen J; Milne, Ginger A; Refaai, Majed A; Francis, Charles F; Phipps, Richard P; Blumberg, Neil. "Isoprostane and isofuran lipid mediators accumulate in stored red blood cells and influence platelet function in vitro". Blood Components. 2014; 54: 1569-1579.
2013 May
Lyman, GH; Khorana, AA; Kuderer, NM; Lee, AY; Arcelus, JI; Balaban, EP; Clarke, JM; Flowers, CR; Francis,CW; Gates, LE; Kakkar, AJ; Key, NS; Levine, MN; Liebman, HA; Tempero, MA; Wong, SL; Prestrud, AA; Falanga, A. "Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Practice Guideline Update." Journal of Clinical Oncology. 2013; . Link
2013 Apr
Francis CW. "Prevention of VTE in patients having major orthopedic surgery." Journal of thrombosis and thrombolysis. 2013 Apr; 35(3):359-67.

Current Appointments

Professor Emeritus - Department of Medicine, Hematology/Oncology (SMD) - Primary


Hematology - American Board of Internal Medicine
Internal Medicine - American Board of Internal Medicine


MD | Medicine | Univ Pittsburgh Sch Medicine1973
BA | Biological Science | Johns Hopkins University1969

Post-Doctoral Training & Residency

Fellowship in Hematology at University of Rochester Medical Center07/01/1976 - 06/30/1979
Residency in Internal Medicine at University of North Carolina Hospitals07/01/1974 - 06/30/1976
Internship in Internal Medicine at University of North Carolina Hospitals07/01/1973 - 6/30/1974